Medtronic (NYSE:MDT) agreed a US$700 million partnership with Cornerstone Robotics to distribute the Sentire surgical system globally.
The Cornerstone deal expands Medtronic’s presence in surgical robotics beyond its existing platforms into a new multi-country distribution arrangement.
Medtronic also partnered with Sonus Microsystems on AI-powered wearable ultrasound technology for maternal health programs in Kenya.
There is more to Medtronic than the Cornerstone and Sonus partnerships described here. Take a look at 5 other big wins we have identified for Medtronic.
For investors tracking how AI and advanced hardware are reshaping healthcare delivery, this Medtronic story connects directly to the broader buildout of 85 AI infrastructure stocks.
NYSE:MDT Earnings & Revenue Growth as at Sep 2026
Medtronic, a US-based medical equipment group with a market value of about US$113.4b, supplies device-based therapies to hospitals and clinicians worldwide, so partnerships in surgical robotics and AI-focused maternal health connect directly with its core role in procedure-focused care.
How does the Cornerstone Robotics deal change Medtronic’s surgical robotics position?
The US$700 million Sentire agreement turns Medtronic into a multi platform player alongside its own Hugo robotic assisted surgery system. Hospitals in Europe, China and Singapore get a broader menu of robotics options at different price points, which can make Medtronic a more flexible partner when procurement teams compare systems.
Does this change the Medtronic Narrative investors have been tracking?
These moves line up directly with the Narrative focus on robotics, digital health and AI enabled ecosystems as key drivers for Medtronic. The Cornerstone and Sonus agreements both lean into that thesis while also adding execution risk, because they increase the number of new platforms Medtronic needs to commercialise effectively.
See how these catalysts shape Medtronic’s path to a $98.00 fair value.
What should you watch next to judge whether these partnerships are working?
The cleanest early signal is how quickly the Sentire and Hugo systems translate into procedure volumes and installed bases at hospitals in Europe, China and Singapore over the next 12 to 24 months. Investors can also track concrete study milestones from the Kenya maternal health program, particularly data readouts on preeclampsia screening performance.
One more thing Medtronic investors cannot ignore
Today’s story only touches the surface of Medtronic’s bigger question, where current analyst projections suggest a future destination that looks very different from what recent headlines imply. See where analysts expect Medtronic to be in a few years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MDT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com